By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.

While some experts speculate the variant could be partially responsible for India’s current surge in SARS-CoV-2 infections, information about the effects of its mutations is only beginning to emerge.

Politicians should of course consider and respect the latest research findings in crafting policy, but elected officials should honor the scientific method by letting its practitioners hash out the details of the science.

Immunization had up to 77 percent efficacy in a Phase 2 clinical study of 450 children in Burkina Faso.

It’s unclear how long protections against infection will last from the initial vaccinations, and health authorities say additional jabs will likely be necessary.

The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.

Vaccinations with the Johnson & Johnson jab paused at several sites earlier this week after an unusual number of people experienced adverse reactions, but the CDC says there’s no cause for concern.

The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks.

One hundred years after its invention, BCG has stood the test of time as a vaccine against tuberculosis.

Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.

Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.

In a triumph for science, COVID-19 statistics are finally trending favorably in the US. We must make sure the rest of the world is not left behind.

Geeta Swamy of Duke University School of Medicine speaks with The Scientist about starting what she considers a long-overdue clinical study of COVID-19 vaccines in pregnant women.

Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.

A case study finds SARS-CoV-2 antibodies in placental cord blood after maternal vaccination.

Preliminary results from an Israel-based study suggest that one dose of the vaccine reduces infectiousness—a key factor in slowing virus spread.

Facing new variants of SARS-CoV-2, some vaccines may offer more robust protection or be more easily redesigned to target them.

Johnson & Johnson’s vaccine is less effective at preventing COVID-19 than other approved vaccines are, but experts say it could still be an important tool in curbing the pandemic.

New data suggest that the company’s approved COVID-19 vaccine protects against different virus variants, but could be less effective against the one that originated in South Africa.